--- title: "17:52 ET CoreAge Rx Expands GLP-1 Access to Support New Year Weight Loss Goals" type: "News" locale: "en" url: "https://longbridge.com/en/news/273142798.md" description: "CoreAge Rx, a telehealth pharmacy, has announced an expansion of its compounded GLP-1 weight management program to support New Year's weight loss goals. This initiative aims to increase access to medications like tirzepatide and semaglutide, addressing barriers such as cost and supply shortages. The expansion includes enhancements to their digital platform and patient education resources, ensuring consistent medication availability. CoreAge Rx's telehealth model allows patients to manage their treatment online, making effective weight management more accessible as many Americans set health resolutions for 2026." datetime: "2026-01-20T22:55:25.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/273142798.md) - [en](https://longbridge.com/en/news/273142798.md) - [zh-HK](https://longbridge.com/zh-HK/news/273142798.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/273142798.md) | [繁體中文](https://longbridge.com/zh-HK/news/273142798.md) # 17:52 ET CoreAge Rx Expands GLP-1 Access to Support New Year Weight Loss Goals , /PRNewswire/ -- CoreAge Rx, a leading telehealth pharmacy specializing in personalized medication services, today announced a strategic New Year's expansion of its compounded GLP-1 weight management program. The expansion provides increased access to compounded tirzepatide and semaglutide, perfectly timed to support Americans pursuing their 2026 health and wellness resolutions. Continue Reading CoreAge Rx (PRNewsfoto/CoreAge Rx) As millions of Americans set ambitious weight loss goals for the new year, CoreAge Rx's expansion addresses surging demand for accessible, affordable GLP-1 medications. Many patients face barriers including cost, insurance limitations, and ongoing supply shortages of brand-name medications. "The start of a new year represents a powerful moment for change, and we're seeing unprecedented interest in medically supported weight management solutions," said Ella Jones, spokesperson for CoreAge Rx. "Our expansion is designed to meet patients where they are—ready to commit to their health goals but facing significant access barriers. We're ensuring that 2026 is the year when effective weight management becomes truly accessible." CoreAge Rx's timing is strategic. Research shows January marks the peak period for health-related goal setting, with weight loss ranking among top New Year's resolutions. However, many individuals struggle to maintain momentum due to challenges in accessing affordable treatment options. CoreAge Rx's compounded GLP-1 medications—prepared by licensed pharmacy partners to rigorous regulatory standards—provide an alternative pathway combining medical efficacy with practical accessibility. The company's comprehensive telehealth model allows patients to complete consultations, receive prescriptions, and manage ongoing treatment entirely online. This approach eliminates traditional barriers for individuals balancing demanding schedules, family responsibilities, and limited access to specialized in-person providers. As part of the New Year's expansion, CoreAge Rx is enhancing its digital platform, strengthening patient education resources, and optimizing fulfillment processes to ensure consistent medication availability during peak demand. The company remains committed to competitive pricing and flexible shipping options. "We're celebrating our patients' commitment to themselves," Jones added. "Our expansion ensures we're ready to support every individual who's decided that 2026 is their year for meaningful, sustainable change." For more information about CoreAge Rx's compounded GLP-1 programs or to begin your 2026 wellness journey, visit https://www.coreagerx.com/. SOURCE CoreAge Rx ### Related Stocks - [Direxion Daily LLY Bull 2X Shares (ELIL.US)](https://longbridge.com/en/quote/ELIL.US.md) - [Defiance Daily Target 2X Long LLY ETF (LLYX.US)](https://longbridge.com/en/quote/LLYX.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md) - [Defiance Daily Target 2X Long NVO ETF (NVOX.US)](https://longbridge.com/en/quote/NVOX.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md) - [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md) - [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md) - [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md) - [Novo Nordisk A/S (NVO.US)](https://longbridge.com/en/quote/NVO.US.md) - [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md) - [Eli Lilly and Company (LLY.US)](https://longbridge.com/en/quote/LLY.US.md) - [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md) - [iShares US Medical Devices ETF (IHI.US)](https://longbridge.com/en/quote/IHI.US.md) - [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md) - [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md) - [SPDR® S&P Health Care Equipment ETF (XHE.US)](https://longbridge.com/en/quote/XHE.US.md) - [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md) ## Related News & Research - [Novo Nordisk Launches Discounted Subscription Program for Wegovy Obesity Drugs -- Update](https://longbridge.com/en/news/281201382.md) - [13:02 ETRO LAUNCHES ELI LILLY'S KWIKPEN®, OFFERING PATIENTS A MORE CONVENIENT WAY TO TAKE ZEPBOUND®](https://longbridge.com/en/news/281557703.md) - [NHS clears Wegovy to reduce risk of heart attack and stroke](https://longbridge.com/en/news/281323250.md) - [BUZZ-Street View: Lilly's $7.8 billion Centessa buyout validates sleep‑drug market](https://longbridge.com/en/news/281367948.md) - [InSilico Medicine Strikes Multi-Billion-Dollar AI Drug Discovery Deal With Eli Lilly](https://longbridge.com/en/news/280909399.md)